Cancer Is Serious Business
About Dr. Stanislaw R. Burzynski
Stanislaw R. Burzynski, M.D., Ph.D., internationally recognized physician and biochemist-researcher who pioneered the development and use of biologically active peptides in diagnosing, preventing and treating cancer, since 1967.
In 1967, at the young age of 24, S.R. Burzynski graduated from the Medical Academy in Lublin, Poland, with a M.D. degree with distinction, finishing first in his class of 250. During the same year he identified naturally occurring peptides in the human body which he concluded control cancer growth. He found that there is a marked deficiency of these peptides in cancer patients.
The following year, 1968, he earned his Ph.D. in Biochemistry as one of the youngest candidates in Poland ever to hold both an M.D. and Ph.D.
From 1970 to 1977, while a researcher and Assistant Professor at Baylor College of Medicine in Houston, his research was sponsored and partially funded by the National Cancer Institute. At Baylor, he authored and co-authored 16 publications, including 5 concerning his research on peptides and their effect on human cancer. Four of these publications were also co-authored by other doctors associated with M.D. Anderson Hospital and Tumor Institute, and Baylor College of Medicine. It was at Baylor that Dr. Burzynski named these peptides "Antineoplastons" due to their activity in correcting and normalizing neoplastic, or cancerous, cells.
In May of 1977, Dr. Burzynski received a Certificate of Appreciation from Baylor College of Medicine, commending him for completing five years of dedicated service and acknowledging his contributions made to the "Advancement of Medical Education, Research, and Health Care."
That same year, Dr. Burzynski founded his clinic in Houston where he's since treated over 8,000 patients. He is also the president of the Burzynski Research Institute, where he continues to pursue scientific research on Antineoplastons.
Dr. Burzynski is a member in good standing of renowned medical associations, including the American and World Medical Associations, American Association for Cancer Research, Society for Neuroscience, Texas Medical Association, Royal Medical Association (U.K.), Academy of Medical Ethics, Society for Neuro-Oncology, and many others.
Dr. Burzynski is the author and co-author of over 300 scientific publications and presentations. In his career he has received numerous prestigious awards from various medical, educational and governmental institutions. Currently, he holds 242 patents registered in 35 countries, related to 17 proprietary scientific inventions (as of January 2011).
Other groups of scientists have expanded Dr. Burzynski's work, including researchers at the National Cancer Institute, the Medical College of Georgia, the Imperial College of Science and Technology of London, the University of Kurume Medical School in Japan, the University of Turin Medical School in Italy, and many others. There are several hundred publications on Antineoplastons and their active ingredients written by scientists working independently of the Burzynski Research Institute.
About the Burzynski Clinic
Established in 1977, the Burzynski Clinic has grown to a world-renowned cancer center, that boasts over 100 employees. The Burzynski Clinic is an exceptional organization that provides cutting-edge, advanced cancer treatments, including Antineoplaston treatment and personalized treatment plans. Burzynski Clinic is world-famous for its discovery of Antineoplastons which have been cleared for Phase III clinical FDA trials (patients must meet clinical criteria).
Our Mission
For over 35 years, Dr. Burzynski's cancer research and care has been inspired by the philosophy of the physician, Hippocrates, to "First, do no harm." True to this philosophy, our treatment regimens are based on the natural biochemical defense system of our body, capable of combating cancer without harming the healthy cells.
Every day, in everything we do, we are proudly committed to these values. Our goal is to continue cancer research. Our mission is to beat cancer.
Personalized Medicine
Instead of a one-size-fits-all approach to cancer treatments, the Burzynski Clinic believes that every patient requires a treatment plan as unique as they are. Burzynski Clinic offers a variety of Personalized Treatment options - designed around the patient's specific needs using custom selected gene targeted medicaitons based on the identification of the oncogenes involved in their cancer. Therapy is highly personalized and designed to selectively kill cancer cells by targeting the abnormal genes in the cancer.
Patients' health and well-being are most important to us.
Our services include: gene-targeted cancer treatment, oncology consultations, genetic markers testing, oncogene testing, in-house pharmacy for formulary management, nutrition counseling, medication training and patient treatment monitoring.
Multilingual Assistance
Due to the international character of our clinic, we are able to assist our patients in various foreign languages, including French, German, Spanish, Portuguese, Russian, Danish, Norwegian, Swedish, Polish, Slovak, Czech, Hungarian, Chinese, Vietnamese, Arabic, Farsi and Hindi.
Stanislaw R. Burzynski, M.D., Ph.D., internationally recognized physician and biochemist-researcher who pioneered the development and use of biologically active peptides in diagnosing, preventing and treating cancer, since 1967.
In 1967, at the young age of 24, S.R. Burzynski graduated from the Medical Academy in Lublin, Poland, with a M.D. degree with distinction, finishing first in his class of 250. During the same year he identified naturally occurring peptides in the human body which he concluded control cancer growth. He found that there is a marked deficiency of these peptides in cancer patients.
The following year, 1968, he earned his Ph.D. in Biochemistry as one of the youngest candidates in Poland ever to hold both an M.D. and Ph.D.
From 1970 to 1977, while a researcher and Assistant Professor at Baylor College of Medicine in Houston, his research was sponsored and partially funded by the National Cancer Institute. At Baylor, he authored and co-authored 16 publications, including 5 concerning his research on peptides and their effect on human cancer. Four of these publications were also co-authored by other doctors associated with M.D. Anderson Hospital and Tumor Institute, and Baylor College of Medicine. It was at Baylor that Dr. Burzynski named these peptides "Antineoplastons" due to their activity in correcting and normalizing neoplastic, or cancerous, cells.
In May of 1977, Dr. Burzynski received a Certificate of Appreciation from Baylor College of Medicine, commending him for completing five years of dedicated service and acknowledging his contributions made to the "Advancement of Medical Education, Research, and Health Care."
That same year, Dr. Burzynski founded his clinic in Houston where he's since treated over 8,000 patients. He is also the president of the Burzynski Research Institute, where he continues to pursue scientific research on Antineoplastons.
Dr. Burzynski is a member in good standing of renowned medical associations, including the American and World Medical Associations, American Association for Cancer Research, Society for Neuroscience, Texas Medical Association, Royal Medical Association (U.K.), Academy of Medical Ethics, Society for Neuro-Oncology, and many others.
Dr. Burzynski is the author and co-author of over 300 scientific publications and presentations. In his career he has received numerous prestigious awards from various medical, educational and governmental institutions. Currently, he holds 242 patents registered in 35 countries, related to 17 proprietary scientific inventions (as of January 2011).
Other groups of scientists have expanded Dr. Burzynski's work, including researchers at the National Cancer Institute, the Medical College of Georgia, the Imperial College of Science and Technology of London, the University of Kurume Medical School in Japan, the University of Turin Medical School in Italy, and many others. There are several hundred publications on Antineoplastons and their active ingredients written by scientists working independently of the Burzynski Research Institute.
About the Burzynski Clinic
Established in 1977, the Burzynski Clinic has grown to a world-renowned cancer center, that boasts over 100 employees. The Burzynski Clinic is an exceptional organization that provides cutting-edge, advanced cancer treatments, including Antineoplaston treatment and personalized treatment plans. Burzynski Clinic is world-famous for its discovery of Antineoplastons which have been cleared for Phase III clinical FDA trials (patients must meet clinical criteria).
Our Mission
For over 35 years, Dr. Burzynski's cancer research and care has been inspired by the philosophy of the physician, Hippocrates, to "First, do no harm." True to this philosophy, our treatment regimens are based on the natural biochemical defense system of our body, capable of combating cancer without harming the healthy cells.
Every day, in everything we do, we are proudly committed to these values. Our goal is to continue cancer research. Our mission is to beat cancer.
Personalized Medicine
Instead of a one-size-fits-all approach to cancer treatments, the Burzynski Clinic believes that every patient requires a treatment plan as unique as they are. Burzynski Clinic offers a variety of Personalized Treatment options - designed around the patient's specific needs using custom selected gene targeted medicaitons based on the identification of the oncogenes involved in their cancer. Therapy is highly personalized and designed to selectively kill cancer cells by targeting the abnormal genes in the cancer.
Patients' health and well-being are most important to us.
Our services include: gene-targeted cancer treatment, oncology consultations, genetic markers testing, oncogene testing, in-house pharmacy for formulary management, nutrition counseling, medication training and patient treatment monitoring.
Multilingual Assistance
Due to the international character of our clinic, we are able to assist our patients in various foreign languages, including French, German, Spanish, Portuguese, Russian, Danish, Norwegian, Swedish, Polish, Slovak, Czech, Hungarian, Chinese, Vietnamese, Arabic, Farsi and Hindi.